Leerink Swann Comments on Teva Pharmaceutical Industries Ltd’s FY2020 Earnings (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Leerink Swann lifted their FY2020 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a report issued on Thursday. Leerink Swann analyst A. Fadia now expects that the company will post earnings per share of $3.11 for the year, up from their previous estimate of $3.10. Leerink Swann has a “Underperform” rating and a $17.00 price objective on the stock. Leerink Swann also issued estimates for Teva Pharmaceutical Industries’ FY2022 earnings at $3.81 EPS.

Several other research firms have also commented on TEVA. Credit Suisse Group set a $20.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, January 22nd. Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, November 27th. Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price target for the company. in a research report on Thursday, January 11th. ValuEngine upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Finally, UBS Group set a $20.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, December 18th. Eight equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $21.76.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $21.33 on Monday. The company has a market capitalization of $21,671.28, a PE ratio of 4.93, a P/E/G ratio of 1.55 and a beta of 0.54. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $37.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%.

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Schwab Charles Investment Management Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock valued at $8,025,000 after purchasing an additional 17,116 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 21.1% in the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock valued at $4,125,000 after purchasing an additional 21,658 shares during the period. Advisor Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 32.8% in the second quarter. Advisor Group Inc. now owns 24,550 shares of the company’s stock valued at $777,000 after purchasing an additional 6,067 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 14.8% in the second quarter. Parametric Portfolio Associates LLC now owns 871,707 shares of the company’s stock valued at $28,958,000 after purchasing an additional 112,067 shares during the period. Finally, QS Investors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 9.1% in the second quarter. QS Investors LLC now owns 90,301 shares of the company’s stock valued at $3,000,000 after purchasing an additional 7,543 shares during the period. Hedge funds and other institutional investors own 51.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/29/leerink-swann-comments-on-teva-pharmaceutical-industries-ltds-fy2020-earnings-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply